The company's preparations for the public availability of COVID-19 vaccinations will focus on supporting its members, including high risk members, who wish to receive a COVID-19 vaccine when it becomes available.
These include members who face language barriers and enrollees facing complex clinical conditions that are further complicated by limited access to the social determinants of health, such as transportation, safe housing and economic stability.
AmeriHealth Caritas' approach to facilitating access to the COVID-19 vaccine reflects its mission.
A community-facing organization with nearly four decades of being embedded in the communities it serves, the company has been nationally recognized for its health equity expertise and its cultural competency in meeting the needs of diverse populations.
AmeriHealth Caritas' collaborative efforts will help its members receive timely, people-centered education about vaccines, including information about when they are available and the appropriate distribution points.
Members of AmeriHealth Caritas' health plans with questions about COVID-19 should contact their plan's Member Services team, found on their Member ID card or on their health plan's website.
AmeriHealth Caritas is one of the nation's leaders in health care solutions for those most in need.
Operating in 13 states and the District of Columbia, AmeriHealth Caritas serves approximately 4.5m Medicaid, Medicare, and Children's Health Insurance Program members through its integrated managed care products, pharmaceutical benefit management and specialty pharmacy services, and behavioral health services.
Headquartered in Philadelphia, AmeriHealth Caritas is a mission-driven organization with more than 37 years of experience serving low-income and chronically ill populations.
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
Ridgetech reports net income of USD10.20m in fiscal year 2025
Genomma Lab Internacional announces Q2 2025 results
Sanofi finalizes acquisition of Blueprint Medicines to expand rare disease and immunology portfolio
CVS Health declares quarterly dividend USD0.665 per share
Lilly declares dividend of USD1.50 for Q3
Bavarian Nordic sells US Priority Review Voucher for USD160m
Bavarian Nordic sells US Priority Review Voucher for USD160m
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea